Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies
文献类型：期刊论文
| 作者 | Jiang, Kai-long1,2; Tong, Le-xian3; Wang, Tao4; Wang, Han-lin1,2,5; Hu, Xiao-bei1,6; Xu, Gao-ya1; Jin, Ting-ting3; Kan, Wei-juan1; Xu, Lei1,2,6; Li, Jia-nan1,7 |
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2021-03-29 |
| 页码 | 9 |
| ISSN号 | 1671-4083 |
| 关键词 | CHK1 inhibitors PY34 drug sensitivity c-Myc hematologic malignancies |
| DOI | 10.1038/s41401-021-00652-1 |
| 通讯作者 | Zhou, Yu-bo(ybzhou@simm.ac.cn) ; Liu, Tao(lt601@zju.edu.cn) ; Yang, Jian-min(chyangjianmin@163.com) ; Li, Jia(jli@simm.ac.cn) |
| 英文摘要 | Checkpoint kinase 1 inhibitors (CHK1i) have shown impressive single-agent efficacy in treatment of certain tumors, as monotherapy or potentiators of chemotherapy in clinical trials, but the sensitive tumor types and downstream effectors to dictate the therapeutic responses to CHK1i remains unclear. In this study we first analyzed GDSC (Genomics of Drug Sensitivity in Cancer) and DepMap database and disclosed that hematologic malignancies (HMs) were relatively sensitive to CHK1i or CHK1 knockdown. This notion was confirmed by examining PY34, a new and potent in-house selective CHK1i, which exhibited potent anti-HM effect in vitro and in vivo, as single agent. We demonstrated that the downregulation of c-Myc and its signaling pathway was the common transcriptomic profiling response of sensitive HM cell lines to PY34, whereas overexpressing c-Myc could partially rescue the anticancer effect of PY34. Strikingly, we revealed the significant correlations between downregulation of c-Myc and cell sensitivity to PY34 in 17 HM cell lines and 39 patient-derived cell (PDC) samples. Thus, our results demonstrate that HMs are more sensitive to CHK1i than solid tumors, and c-Myc downregulation could represent the CHK1i efficacy in HMs. |
| 资助项目 | National Natural Science Foundation of China[81673466] ; National Natural Science Foundation of China[81821005] ; National Natural Science Foundation of China[21772174] ; National Natural Science Foundation of China[81172929] ; Personalized Medicines-Molecular Signature-based Drug Discovery and Development ; Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12020214] ; National Science and Technology Major Project of China[2018ZX09711002-011-015] ; Science and Technology Commission of Shanghai Municipality[16431902200] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | NATURE PUBLISHING GROUP |
| WOS记录号 | WOS:000634685300002 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/295344]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Zhou, Yu-bo; Liu, Tao; Yang, Jian-min; Li, Jia |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 3.Zhejiang Univ, Coll Pharmaceut Sci, ZJU ENS Joint Lab Med Chem, Zhejiang Prov Key Lab Anti Canc Drug Res, Hangzhou 310058, Peoples R China 4.Naval Med Univ, Changhai Hosp, Shanghai 200433, Peoples R China 5.Shanghai Tech Univ, Shanghai 201210, Peoples R China 6.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Inst Drug Discovery & Dev, Zhongshan 528400, Peoples R China 7.Nanjing Univ Chinese Med, Coll Pharm, Nanjing 210033, Peoples R China |
| 推荐引用方式 GB/T 7714 | Jiang, Kai-long,Tong, Le-xian,Wang, Tao,et al. Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies[J]. ACTA PHARMACOLOGICA SINICA,2021:9. |
| APA | Jiang, Kai-long.,Tong, Le-xian.,Wang, Tao.,Wang, Han-lin.,Hu, Xiao-bei.,...&Li, Jia.(2021).Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies.ACTA PHARMACOLOGICA SINICA,9. |
| MLA | Jiang, Kai-long,et al."Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies".ACTA PHARMACOLOGICA SINICA (2021):9. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。